In:
Pharmacoepidemiology and Drug Safety, Wiley, Vol. 31, No. 6 ( 2022-06), p. 614-622
Kurzfassung:
Tramadol may lower the seizure threshold; however, there is no conclusive evidence to confirm this. This study aimed to determine whether the use of tramadol is associated with the occurrence of seizures. Methods We conducted a case–case‐time‐control (CCTC) study by identifying patients who had received tramadol and seizure diagnosis in a nationwide healthcare database in South Korea between 2003 and 2015. Each case was matched for age and sex to one future case to adjust for time trends in exposure without selection bias from the use of an external control group. The use of tramadol was assessed during a risk period of 1–30 days, and two reference periods, 61–90 days and 91–120 days, preceding the first diagnosis of seizures. We calculated the adjusted odds ratio (aOR) by dividing the OR in cases (case‐crossover) by the OR in future cases (control‐crossover). We performed a dose–response analysis using the average daily dose. Results We identified 2523 incident cases with matched future cases (mean age, 45.4 years; 50% men). The aOR for seizure with tramadol use was 0.94 (95% confidence interval [CI], 0.98–1.43) in the CCTC analysis, with a case‐crossover OR of 1.19 (0.98–1.43) and control‐crossover OR of 1.27 (1.03–1.56). The dose–response analysis showed a similar trend in the main analysis: a low‐dose aOR of 0.80 (0.50–1.28) and a high‐dose aOR of 0.92 (0.41–2.11). Conclusion We could not identify a significant association between transient use of tramadol and incidence of seizures in clinical practice.
Materialart:
Online-Ressource
ISSN:
1053-8569
,
1099-1557
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2022
ZDB Id:
1491218-1
SSG:
15,3
